These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
792 related articles for article (PubMed ID: 24244612)
1. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612 [TBL] [Abstract][Full Text] [Related]
2. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826 [TBL] [Abstract][Full Text] [Related]
3. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Simioni C; Cani A; Martelli AM; Zauli G; Tabellini G; McCubrey J; Capitani S; Neri LM Oncotarget; 2014 Oct; 5(20):10034-47. PubMed ID: 25296981 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660 [TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800 [TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
8. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370 [TBL] [Abstract][Full Text] [Related]
9. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518 [TBL] [Abstract][Full Text] [Related]
11. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Singh P; Kumar V; Gupta SK; Kumari G; Verma M Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624 [TBL] [Abstract][Full Text] [Related]
12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
13. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863 [TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685 [TBL] [Abstract][Full Text] [Related]
16. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
17. Current development of the second generation of mTOR inhibitors as anticancer agents. Zhou HY; Huang SL Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905 [TBL] [Abstract][Full Text] [Related]
18. Orexin A protects cells from apoptosis by regulating FoxO1 and mTORC1 through the OX1R/PI3K/AKT signaling pathway in hepatocytes. Ju SJ; Zhao Y; Chang X; Guo L Int J Mol Med; 2014 Jul; 34(1):153-9. PubMed ID: 24807827 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524 [TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Barrett D; Brown VI; Grupp SA; Teachey DT Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]